9 MAR 2026
CR2O at The Future of Advanced Therapies
London 17-18 March 2026
CR2O is pleased to attend the Advanced Therapies Congress in London, a major European meeting focused on the development and commercialization of advanced therapies including cell therapy, gene therapy, and other ATMPs. The congress brings together biotech innovators, translational scientists, investors, and clinical development partners working to translate cutting edge science into real treatments for patients.
At CR2O we specialize in early clinical development, supporting companies as they move from preclinical research into first in human and early phase clinical trials. Our expertise lies particularly in gene therapy, immunology driven programs, vaccines, and complex ATMP development where strong translational planning and immune readouts are critical to demonstrate early proof of concept.
Through our experience in early stage studies and advanced therapeutic modalities, we help biotech companies design efficient clinical programs, define meaningful biological endpoints, and navigate the regulatory pathway from IND planning through early clinical execution.
If you are attending the congress and developing a gene therapy, immunology, or other advanced therapy program, we would be happy to connect and exchange perspectives.